ZBH Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of 11.84% compared to Zimmer Biomet Holdings's net margin of 54.53%. Zimmer Biomet Holdings's return on equity of 7.21% beat NeuroOne Medical Technologies's return on equity of -238.93%.

Zimmer Biomet Holdings has a consensus price target of $122.27, signalling upside risk potential of 13.91%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 321.05%. Given that NeuroOne Medical Technologies has higher upside potential than Zimmer Biomet Holdings, analysts believe NeuroOne Medical Technologies is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 0.843, which suggesting that the stock is 15.664% less volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.823%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.89%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $2B, which are larger than NeuroOne Medical Technologies quarterly revenues of $3.3M. Zimmer Biomet Holdings's net income of $239.5M is higher than NeuroOne Medical Technologies's net income of $1.8M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 24.12x while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.85x versus 2.35x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 11.84% compared to Zimmer Biomet Holdings's net margin of 26.88%. Zimmer Biomet Holdings's return on equity of 7.21% beat ResMed's return on equity of 25.56%.

Zimmer Biomet Holdings has a consensus price target of $122.27, signalling upside risk potential of 13.91%. On the other hand ResMed has an analysts' consensus of $269.42 which suggests that it could grow by 31.32%. Given that ResMed has higher upside potential than Zimmer Biomet Holdings, analysts believe ResMed is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 0.843, which suggesting that the stock is 15.664% less volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.89%. ResMed offers a yield of 1.01% to investors and pays a quarterly dividend of $0.53 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $2B, which are larger than ResMed quarterly revenues of $1.3B. Zimmer Biomet Holdings's net income of $239.5M is lower than ResMed's net income of $344.6M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 24.12x while ResMed's PE ratio is 24.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.85x versus 6.14x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 11.84% compared to Zimmer Biomet Holdings's net margin of 12.66%. Zimmer Biomet Holdings's return on equity of 7.21% beat Steris PLC's return on equity of 7.27%.

Zimmer Biomet Holdings has a consensus price target of $122.27, signalling upside risk potential of 13.91%. On the other hand Steris PLC has an analysts' consensus of $250.13 which suggests that it could grow by 17.65%. Given that Steris PLC has higher upside potential than Zimmer Biomet Holdings, analysts believe Steris PLC is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 0.843, which suggesting that the stock is 15.664% less volatile than S&P 500. In comparison Steris PLC has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.657%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.89%. Steris PLC offers a yield of 1.05% to investors and pays a quarterly dividend of $0.57 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Steris PLC pays out 53.03% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $2B, which are larger than Steris PLC quarterly revenues of $1.4B. Zimmer Biomet Holdings's net income of $239.5M is higher than Steris PLC's net income of $173.5M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 24.12x while Steris PLC's PE ratio is 45.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.85x versus 3.91x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 11.84% compared to Zimmer Biomet Holdings's net margin of 8.48%. Zimmer Biomet Holdings's return on equity of 7.21% beat Stryker's return on equity of 15.22%.

Zimmer Biomet Holdings has a consensus price target of $122.27, signalling upside risk potential of 13.91%. On the other hand Stryker has an analysts' consensus of $423.40 which suggests that it could grow by 22.44%. Given that Stryker has higher upside potential than Zimmer Biomet Holdings, analysts believe Stryker is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 0.843, which suggesting that the stock is 15.664% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.89%. Stryker offers a yield of 0.95% to investors and pays a quarterly dividend of $0.84 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $2B, which are smaller than Stryker quarterly revenues of $6.4B. Zimmer Biomet Holdings's net income of $239.5M is lower than Stryker's net income of $546M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 24.12x while Stryker's PE ratio is 44.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.85x versus 5.90x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.